📊 LAB Key Takeaways
Is Standard Biotools Inc.. (LAB) a Good Investment?
Standard Biotools exhibits a critical disconnect between balance sheet strength and operational deterioration. Despite $265.8M in cash and negligible debt, the company generated negative operating cash flow (-$46.6M) and negative free cash flow (-$47.2M), indicating unsustainable cash burn. The abnormally high net income (600.9% margin) appears driven by one-time items, masking operational losses and declining revenue that signal fundamental business challenges.
Standard BioTools shows solid gross margins and a strong, low-leverage balance sheet, but fundamentals are dominated by sizable operating losses and negative free cash flow. With revenue contracting and no clear evidence of cost discipline closing the gap to profitability, risk remains elevated until cash burn materially improves.
Why Buy Standard Biotools Inc.. Stock? LAB Key Strengths
- Fortress balance sheet with $561.1M equity and minimal debt exposure
- Exceptional liquidity position with 12.36x current ratio and $265.8M cash reserves providing downside protection
- Healthy gross margin of 53.5% demonstrates product-level profitability before operating overhead
- Strong liquidity with sizable cash and high current/quick ratios
- Minimal leverage (near-zero debt) reduces insolvency risk
- Healthy gross margin (~50%) supports potential operating leverage if scale returns
LAB Stock Risks: Standard Biotools Inc.. Investment Risks
- Severe negative operating cash flow (-$46.6M) and free cash flow (-$47.2M) indicate unsustainable cash consumption
- Operating losses (-$12.5M) with -59.1% operating margin show core business is not profitable
- Revenue decline of 6.2% YoY signals weakening market demand or competitive position
- Net income appears artificially inflated by one-time gains, masking operational deterioration; cash burn threatens viability within 5-6 years at current rate
- Large operating and net losses with deeply negative FCF
- Revenue decline (-6.2% YoY) signals weak demand/execution challenges
- Potential need for external financing if cash burn persists
Key Metrics to Watch
- Operating cash flow trend and path to positive OCF
- Revenue stabilization and return to growth
- Operating margin improvement and timeline to operating profitability
- Revenue growth trajectory (YoY and sequential)
- Operating cash flow/free cash flow trend toward breakeven
Standard Biotools Inc.. (LAB) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 12.36x current ratio provides a solid financial cushion.
LAB Profit Margin, ROE & Profitability Analysis
LAB vs Industrial Sector: How Standard Biotools Inc.. Compares
How Standard Biotools Inc.. compares to Industrial sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Standard Biotools Inc.. Stock Overvalued? LAB Valuation Analysis 2026
Based on fundamental analysis, Standard Biotools Inc.. appears fundamentally strong relative to the Industrial sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Standard Biotools Inc.. Balance Sheet: LAB Debt, Cash & Liquidity
LAB Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Standard Biotools Inc..'s revenue has declined by 23% over the 5-year period, indicating business contraction. The most recent EPS of $-0.94 indicates the company is currently unprofitable.
LAB Revenue Growth, EPS Growth & YoY Performance
LAB Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $20.2M | -$26.0M | $-0.07 |
| Q3 2025 | $19.6M | -$26.0M | $-0.07 |
| Q2 2025 | $21.8M | -$26.0M | $-0.09 |
| Q1 2025 | $40.8M | -$26.0M | $-0.07 |
| Q3 2024 | $25.1M | -$16.8M | $-0.07 |
| Q2 2024 | $27.7M | -$16.8M | $-0.12 |
| Q3 2023 | $25.4M | -$16.8M | $-0.27 |
| Q2 2023 | $18.8M | -$16.8M | $-0.22 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Standard Biotools Inc.. Dividends, Buybacks & Capital Allocation
LAB SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Standard Biotools Inc.. (CIK: 0001162194)
📋 Recent SEC Filings
❓ Frequently Asked Questions about LAB
What is the AI rating for LAB?
Standard Biotools Inc.. (LAB) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 76% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are LAB's key strengths?
Claude: Fortress balance sheet with $561.1M equity and minimal debt exposure. Exceptional liquidity position with 12.36x current ratio and $265.8M cash reserves providing downside protection. ChatGPT: Strong liquidity with sizable cash and high current/quick ratios. Minimal leverage (near-zero debt) reduces insolvency risk.
What are the risks of investing in LAB?
Claude: Severe negative operating cash flow (-$46.6M) and free cash flow (-$47.2M) indicate unsustainable cash consumption. Operating losses (-$12.5M) with -59.1% operating margin show core business is not profitable. ChatGPT: Large operating and net losses with deeply negative FCF. Revenue decline (-6.2% YoY) signals weak demand/execution challenges.
What is LAB's revenue and growth?
Standard Biotools Inc.. reported revenue of $21.1M.
Does LAB pay dividends?
Standard Biotools Inc.. does not currently pay dividends.
Where can I find LAB SEC filings?
Official SEC filings for Standard Biotools Inc.. (CIK: 0001162194) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LAB's EPS?
Standard Biotools Inc.. has a diluted EPS of $0.33.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is LAB a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Standard Biotools Inc.. has a SELL rating with 76% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is LAB stock overvalued or undervalued?
Valuation metrics for LAB: ROE of 22.6% (sector avg: 15%), net margin of 600.9% (sector avg: 10%). Higher ROE suggests strong returns relative to peers.
Should I buy LAB stock in 2026?
Our dual AI analysis gives Standard Biotools Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is LAB's free cash flow?
Standard Biotools Inc..'s operating cash flow is $-46.6M, with capital expenditures of $570.0K. FCF margin is -223.1%.
How does LAB compare to other Industrial stocks?
Vs Industrial sector averages: Net margin 600.9% (avg: 10%), ROE 22.6% (avg: 15%), current ratio 12.36 (avg: 1.8).